\n<\/p>\n
The Justice Department moved Friday to block a lawsuit from Missouri challenging the Food and Drug Administration (FDA) for allowing the abortion drug mifepristone to be shipped through the mail.\u00a0<\/span><\/p>\n A <\/span>filing<\/span><\/a> from the DOJ argued that allowing the suit to move forward would inhibit a safety study on the abortion pill being conducted by the Trump administration. Missouri and several other Republican-led states have asked a judge to block a COVID-era policy that relaxed regulations for dispensing the abortion pill.\u00a0<\/span><\/p>\n \u201cMissouri, Kansas, and Idaho are not the only plaintiffs to have challenged the current conditions of use for mifepristone,\u201d the Justice Department wrote. \u201cGiven this widespread debate over the safety of mifepristone, FDA has concluded that the best path forward is for the agency to undertake its review based on all the evidence before the agency.\u201d<\/span><\/p>\n The filing asked the judge to put the lawsuit on hold while the FDA reviews the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone or dismiss the case altogether. It comes as pro-life <\/span>advocates<\/span><\/a> and <\/span>lawmakers<\/span><\/a> have called for the Trump administration to crack down on mail-order abortion pills.\u00a0<\/span><\/p>\n Last year, FDA Administrator Marty Makary and Health and Human Services Director Robert F. Kennedy Jr. said that they initiated the REMS review. The study has yet to be released, and pro-life lawmakers and advocates have grown impatient as abortions continue to increase in states where medication abortion is banned due to an influx of outside pills.\u00a0<\/span><\/p>\n A spokesman for the Justice Department told The Daily Wire that the intent of the filing was to allow the FDA to oversee drug policy, not the federal court system.\u00a0<\/span><\/p>\n \u201cIn this filing, the Department of Justice requested more time from the court for the FDA to complete its review of mifepristone REMS,\u201d the spokesman said. \u201cAs the Supreme Court recognized in a unanimous ruling less than two years ago, it is the role of the FDA \u2013 not the federal courts \u2013 to evaluate drug safety data and impose appropriate precautions.\u201d<\/span><\/p>\n The filing from the DOJ dismisses concerns from pro-life states that FDA policies allow abortionists to ship pills into their states. The department said that states \u201cremain free to make and enforce their pro-life policies\u201d and that the federal government is not \u201cstanding in the way of Intervenor Plaintiffs enforcing their abortion laws against out-of-state prescribers of mifepristone.\u201d<\/span><\/p>\n The filing mirrors another<\/a> one from January, where the DOJ asked a judge not to grant a request from Louisiana also seeking to block the FDA\u2019s abortion pill mailing policy.<\/p>\n